United States Patent 9,844,544: Scope, Claim Fences, and US Landscape for Racemic Methylphenidate ER Chewable
US 9,844,544 is a method and product patent that claims a specific extended release (ER) chewable architecture for racemic methylphenidate (R-MPH). The central claim fence is a uniform solid dispersion delivering a split-release system: (i) a sustained release racemic methylphenidate–ion exchange resin complex with a pH-independent water-insoluble, water-permeable barrier coating in a polymeric matrix and (ii) two immediate-release (IR) species that are structurally distinct (an uncoated R-MPH–ion exchange resin complex and an uncomplexed R-MPH acceptable salt, with IR onset discrimination). The patent also hard-codes pharmacokinetic (PK) targets, dose equivalence (40 mg R-MPH HCl), and divisibility that preserves ER performance in tablet halves/portions.
The patent’s practical risk is not generic “once-daily methylphenidate ER.” It is closer to a formulation/process claim set that requires meeting specific compositional and performance constraints simultaneously: resin complex type + barrier-coat chemistry + resin complex ratios + ER/IR weight fractions + in vitro dissolution behavior + single-peaked PK and specific AUC/Cmax bands after a single chewable dose (fasted and/or fed depending on the claim).
What does claim 1 actually require (independent claim scope)?
Core claim type
Claim 1 is a method of treating a patient (disorder “treatable by methylphenidate”) by providing an ER chewable tablet with a defined internal structure and PK profile.
Structural and functional requirements in claim 1
Claim 1 requires the following, in combination:
-
Uniform solid dispersion chewable tablet containing:
- (a) Sustained release component
- A sustained release racemic methylphenidate component comprising a water-insoluble, water-permeable, pH-independent barrier coated racemic methylphenidate–ion exchange resin complex in a polymeric matrix.
- The barrier coating must provide the sustained release profile to the complex-matrix, and claim language ties the barrier coating to the complex-matrix: “barrier coating … is over the … complex-matrix.”
- (b) First immediate release component
- An immediate release uncoated racemic methylphenidate–ion exchange resin complex.
- (c) Second immediate release component
- Uncomplexed racemic methylphenidate acceptable salt.
-
Release timing constraint
- IR component (b) has a slower onset of release than IR component (c).
-
Weight fraction of ER
- 50% w/w to 90% w/w of the racemic methylphenidate active is provided by the sustained release component, based on total racemic methylphenidate in the tablet.
-
Divisibility while preserving ER
- Tablet is capable of being divided and tablet portions retain a therapeutically effective extended release profile and a pharmacokinetic profile.
-
Hard PK targets (single administration, 40 mg R-MPH HCl equivalent)
- After single oral administration of the chewable tablet (equivalent of 40 mg racemic methylphenidate HCl), methylphenidate must have at least one of the following under fasted and fed conditions in adults:
- Geometric mean AUC0-∞: about 110 to 140 ng·hr/mL
- Geometric mean Cmax: about 10 to 15 ng/mL
Scope implication
To infringe claim 1, a challenger must show both:
- The formulation architecture (barrier-coated resin complex in polymeric matrix + two distinct IR entities with onset discrimination), and
- The in vivo PK performance within at least one of the numeric bands, plus divisibility that preserves ER.
This creates a high “all-elements” burden for design-around because PK can change with small formulation differences (barrier thickness, plasticizer, resin loading, matrix polymer type, chewing/meal effects, and IR release contribution).
How do dependent claims tighten the fences (1–40)?
Patient population (claim 2)
Claim 2 limits the method to patients diagnosed with one of:
PK refinement (claims 3–4)
- Claim 3: Cmax about 12 to 13 ng/mL
- Claim 4: AUC0-∞ about 113 to 138 ng·hr/mL
These are narrower “sweet spots” within claim 1’s ranges.
ER vs IR weight fractions (claims 5–8, 11, 12)
- Claim 5: sustained release provides about 60% to 80% w/w
- Claim 6: total of IR components (uncoated resin complex + uncomplexed salt) is 20% to 40% w/w
- Claim 7: IR resin complex (b) to uncomplexed salt (c) ratio about 3:1 by total weight of IR components
- Claim 8: uncoated immediate-release resin complex (b) about 5% to 35% w/w of total R-MPH
- Claim 11: uncomplexed IR salt (c) about 5% to 35% w/w
- Claim 12: specific pair example:
- (b) about 15% w/w of total R-MPH
- (c) about 15% w/w of total R-MPH
Dose variants (claims 24–26)
Claim 1 anchors to 40 mg equivalence. Dependent claims also recite:
- Claim 25: 30 mg
- Claim 26: 20 mg
Mechanical property (claim 13, 35)
- Tablet hardness 8 kp to 23 kp
Barrier coating chemistry and mechanics (claims 14–16, 19, 38–40)
Claim 14 defines the barrier coat as water-insoluble, water-permeable, pH-independent, with elongation factor:
- elongation factor about 150% to 400%
- Barrier coat options:
- (a) cured PVAc-based aqueous dispersion (PVAc + stabilizer + plasticizer)
- (b) ionic pH-independent acrylic based coating (ethyl acrylate and methyl methacrylate polymer/copolymer) in aqueous dispersion
- (c) solvent-based ethylcellulose coating optionally with plasticizer
Claim 15 tightens option (a):
- barrier coat comprises about 70–90% w/w PVAc, 2–10% plasticizer (with stabilizer)
Claim 16:
- barrier coating layer is about 25% to 35% by weight of the coated R-MPH–resin complex-matrix.
Claim 19 adds a specific acrylic blend composition:
- blend ratio examples for poly(ethyl acrylate-co-methyl methacrylate-co-trimethylammonioethyl methacrylate chloride) at 1:2:0.1 and 1:2:0.2 (as two blend components)
Claim 38 / 39 / 40:
- Claim 38: barrier coat elongation factor 150% to 400% by texture analyzer
- Claim 39: barrier coat selected from the same three categories as claim 14, but recast as explicit selections
- Claim 40: plasticizer amount about 2.5% to 20% by weight of the coating
Matrix polymer specification (claims 17–18)
- Claim 17: polymeric matrix comprises polyvinylpyrrolidone (PVP)
- Claim 18: matrix further comprises a water-insoluble polymer
Outer coating and excipients (claims 20–21)
- claim 20: non-functional outer top coating layer
- claim 21: tablet comprises one or more excipients (broad)
PK single-peak requirement (claims 22–23, 37)
- Claim 22: PK profile for racemic methylphenidate with single mean plasma concentration peak
- Claim 23: peak between 4 to 5.25 hours under fasted and fed conditions in adults
- Claim 37: again single mean concentration peak
This is a design constraint: a two-peak profile can fall outside the claim depending on how “single mean peak” is tested/defined.
In vitro dissolution assay parameters (claims 27? not specified; claim 36)
- Claim 27: scored tablet
- Claim 36: dissolution assay uses:
- 900 mL
- 0.4 M potassium phosphate buffer
- 37°C ± 5°C
- USP paddle speed 75 rpm
Claim 28 (product claim) also uses an IR definition:
- at least one IR component provides release in less than about 30 minutes as determined in in vitro dissolution assay.
Plasticizer selections (claims 29–30)
- Claim 29 lists plasticizers (examples include propylene glycol, PEG, dibutyl sebacate, PVA, triethyl citrate, acetyl triethyl citrate, acetyl tributyl citrate, tributyl citrate, triacetin, 2-pyrrolidone, mixtures)
- Claim 30: plasticizer comprises triethyl citrate
Product claim (claim 28) provides alternate infringement route
Claim 28 is an extended release racemic methylphenidate chewable tablet with a similar component architecture, but framed as a product:
- sustained release barrier-coated R-MPH cation exchange resin complex in barrier coat
- at least one immediate release component provides release in <30 minutes
- chewable divisibility and PK conditions under fasted conditions
This matters because a competitor could potentially design an ER product meeting the claimed composition/performance without directly using the method language.
Independent product claim 28: what changes vs claim 1
Claim 28 tracks claim 1 but changes testing conditions and some wording:
- PK conditions: geometric mean AUC0-∞ and/or Cmax under fasted conditions in adults after a single oral administration of a chewable tablet with 40 mg equivalence.
- It removes the explicit statement “fasted and fed conditions” found in claim 1 and instead says fasted for the PK.
- IR definition uses an in vitro threshold:
- release “less than about 30 minutes” in a dissolution assay.
The barrier coating is described as:
- “water-insoluble, water-permeable, pH-independent polymer and a plasticizer”
- barrier coating amount:
- about 20% w/w to about 50% w/w based on the weight of the R-MPH-cation exchange resin complex.
Patent landscape mapping: what this patent blocks (and what it does not)
Likely competitive “design-around” targets
To avoid infringement, a generic or new entrant must typically break at least one critical element. The claims concentrate infringement risk on four axes:
- Resin complex ER with pH-independent barrier coat
- Barrier must be water-insoluble, water-permeable, and pH-independent, and be positioned “over” the resin complex-matrix.
- Two IR species with onset discrimination
- uncoated resin complex IR (b) vs uncomplexed salt IR (c), with (b) slower onset than (c).
- ER/IR weight fractions
- Sustained release typically 50–90% (and often tightened to 60–80% in dependent claims).
- PK profile numerics and single-peak shape
- AUC and/or Cmax target bands plus single mean peak constraint.
A competitor can potentially redesign by:
- removing the pH-independent barrier-coated resin ER architecture,
- eliminating the split IR system,
- altering ER fraction so it falls outside 50–90% (or dependent claim 60–80%),
- shifting PK out of the claimed AUC/Cmax bands or producing more than one mean peak.
What the patent does not do well (freedom-to-operate limitations)
The claim set is tight on chewable ER tablets using the described internal complexes and barrier systems. It does not, on its own, broadly cover:
- standard ER tablet forms without chewable uniform solid dispersion architecture,
- methylphenidate ER products that do not use a resin complex ER with the specified barrier coating and IR dual-entity release scheme,
- non-chewable formats unless they satisfy the claim’s “chewable” and divisibility constraints.
Practical landscape conclusion
In the US, this patent functions as a formulation and performance blockade for ER racemic methylphenidate chewables built around:
- resin-complex ER with pH-independent barrier,
- split IR release with uncoated resin complex + uncomplexed salt,
- divisibility preserving ER,
- single-peaked PK with AUC/Cmax bands.
Claim-to-technology translation (what an accused product must look like)
| Claim element |
Functional requirement |
“Looks like” in product terms |
| Sustained release component (a) |
sustained release racemic MPH–ion exchange resin complex in polymeric matrix with pH-independent, water-insoluble/water-permeable barrier over the complex-matrix |
barrier-coated resin pellets/particles dispersed in matrix, barrier composition within enumerated options |
| Immediate release component (b) |
uncoated IR racemic MPH–ion exchange resin complex |
same resin complex without the barrier layer used on ER particles |
| Immediate release component (c) |
uncomplexed racemic MPH acceptable salt (often HCl) |
bulk salt form powder or embedded salt fraction |
| Onset discrimination |
(b) onset slower than (c) |
IR formulation kinetics must delay resin-complex dissolution vs free salt dissolution |
| ER fraction |
ER 50–90% of active by weight |
active mass distribution heavily weighted to barrier-coated resin ER fraction |
| Divisibility |
halves retain ER + PK profile |
scored or otherwise divisible chewable that preserves particle distribution and ER release |
| PK numerics |
AUC0-∞ ~110–140 and/or Cmax ~10–15; single mean peak |
clinical PK profile aligned to geometric mean bands |
Key Takeaways
- US 9,844,544 blocks an ER racemic methylphenidate chewable “split architecture”: barrier-coated ER resin complex in a polymeric matrix plus two distinct IR components (uncoated resin complex and uncomplexed salt) with onset discrimination.
- Infringement is performance-sensitive: claimed products must hit specific PK ranges (AUC0-∞ and/or Cmax) after a single 40 mg equivalent dose and show a single mean concentration peak.
- Dependent claims substantially narrow formulation space by pinning barrier coat chemistry (PVAc-based, acrylic-based, or ethylcellulose), barrier mechanics (elongation factor), matrix polymer (PVP), IR/ER ratios, and mechanical tablet hardness.
- Design-around is possible but costly: removing or altering any one of the four axes (barrier-coated pH-independent ER resin complex, dual IR entity scheme with onset discrimination, ER fraction, or PK band/single-peak behavior) is the typical route.
FAQs
-
Is the patent limited to racemic methylphenidate HCl specifically?
No. The claims focus on racemic methylphenidate and specify that the uncomplexed IR acceptable salt can be, for example, racemic methylphenidate HCl (dependent claim 10), but claim 1 also allows “acceptable salt.”
-
Does infringement require both AUC and Cmax to match?
Claim 1 requires at least one of the two PK metrics (AUC0-∞ or Cmax) to fall within the stated geometric mean bands under the defined conditions.
-
What is the highest-risk formulation feature for a competitor?
The combination of pH-independent water-insoluble/water-permeable barrier coating over a racemic methylphenidate–ion exchange resin complex in a polymeric matrix, paired with two IR entities with onset ordering.
-
Can a new product avoid the patent by changing the barrier polymer from PVAc to acrylic?
The barrier polymer substitution is not automatically safe because the claims list multiple acceptable barrier chemistries and still require the same functional attributes (pH-independent, water-insoluble/water-permeable, elongation factor range, and positioning over the complex-matrix).
-
Does tablet divisibility matter for infringement?
Yes. Both claim 1 and claim 28 require that the chewable tablet is divisible and that portions retain an extended release profile and PK profile.
References
[1] US Patent 9,844,544 (claim text provided in prompt).
